Navigation Links
Velcade(R) Plus Doxil(R) Improves Previously Treated Multiple Myeloma Patients

NORTH HOLLYWOOD, Calif., and CHICAGO, The International Myeloma Foundation (IMF)-supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians-today said that data from a follow-up to a Phase 3 multi- national clinical trial shows the combination of DOXIL(R) with VELCADE(R) improves the probability of survival by 41%.

The follow-up study also showed no increase in serious side effects such as neuropathy with the addition of DOXIL to the VELCADE. The findings were presented at the American Society of Clinical Oncology (ASCO) global cancer meeting in Chicago.

The VELCADE/DOXIL combination was approved by the FDA just last month as a new treatment option for myeloma patients who have relapsed or who have not responded to at least one other course of treatment. The drugs work in combination because there is evidence that VELCADE increases the effectiveness of DOXIL against cancer cells and DOXIL does the same for VELCADE.

"'Improved survival' are words that every cancer patient wants to hear, and we are encouraged to have this new option to offer patients with peer reviewed data behind it," said Susie Novis, president and co-founder of the IMF. "Until there is a cure, we are moving myeloma toward becoming a chronic disease with long term survival achieved by using drugs in combination and in sequence. The VELCADE/DOXIL combination fits perfectly into this paradigm and offers an important and powerful new opportunity to extend and improve patients' lives."

DOXIL is a specially (liposomal) formulated version of the chemotherapy agent doxorubicin, and is approved for use in other forms of cancer. VELCADE, bortezomib, is approved for myeloma patients who have relapsed or not responded to a previous course of treatment. The findings come from a 14 month follow-up to a multi-national trial involving nearly 650 patients.

Myeloma, also called mul tiple myeloma, is a cancer of the bone marrow that affects production of red cells, white cells and stem cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.


'"/>




Related medicine news :

1. Hypertensive Drug Improves Sexual Dysfunction in Hypertensive Men
2. Sage Improves Memory
3. Combination Therapy Found To Improves Stroke Recovery
4. Caffeine Boosts Memory, Improves Attention Span
5. Children’s Health Improves By Swimmin
6. Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients
7. Folic Acid Improves Survival Rate Of Children With Birth Defects
8. Drug Combo Improves Performance Of Multiple Sclerosis Drug
9. Weight Training Improves Quality Of Life In Breast Cancer Patients
10. Ginseng Improves The Survival Rates Of Breast Cancer
11. Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/25/2017)... ... April 25, 2017 , ... ... agreement to be the preferred physical therapy provider for Derby City CrossFit, effective ... Derby City CrossFit as quickly and effectively as possible, ProRehab’s sports physical therapists ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent ... test score performance for the 2015-16 school year across Wisconsin’s public schools, charter ... it highlights important patterns in student test score performance, the report’s limited analyses ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... contracted partners to help with process innovation in drug formulation and manufacturing. ... along with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
Breaking Medicine Technology: